AiCure, a NYC-based Artificial Intelligence company connecting patients with a mobile solution to visually confirm medication ingestion, raised $12.25m in Series A funding.
The round was led by New Leaf Venture Partners, with participation from Pritzker Group Venture Capital, Tribeca Venture Partners, and Biomatics Capital, established by Boris Nikolic, former Chief Advisor for Science and Technology to Bill Gates. In conjunction with the funding, Vijay Lathi, managing director of New Leaf, joined AiCure’s board of directors.
Led by Adam Hanina, CEO, AiCure provides a mobile software-as-a-service (SaaS) platform that applies machine learning, computer vision, and big data to health care. The technology solution, which uses artificial intelligence to visually confirm medication ingestion, has been validated against drug levels in blood samples, and across other patient populations, from elderly stroke patients to study participants in schizophrenia and HIV prevention trials.
The company partners with pharmaceutical companies and government institutions to allow them to monitor medication adherence and optimize treatment models.